Peer Review History
| Original SubmissionMarch 16, 2022 |
|---|
|
PONE-D-22-07908Impact of maternal protein restriction on hypoxia-inducible factor (HIF) expression in male fetal kidney developmentPLOS ONE Dear Dr. Gontijo, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. In particular there needs to be a greater justification of the choice (and limitations) of choosing d17 as a snap shot and other methodological queries highlighted by the reviewers. Equally, more structure and review of the manuscript might clarify some of the issues arising. Please submit your revised manuscript by Jun 17 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:
If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols. We look forward to receiving your revised manuscript. Kind regards, Christopher Torrens Academic Editor PLOS ONE Journal Requirements: When submitting your revision, we need you to address these additional requirements. 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf 2. As part of your revision, please complete and submit a copy of the Full ARRIVE 2.0 Guidelines checklist, a document that aims to improve experimental reporting and reproducibility of animal studies for purposes of post-publication data analysis and reproducibility: https://arriveguidelines.org/sites/arrive/files/Author%20Checklist%20-%20Full.pdf (PDF). Please include your completed checklist as a Supporting Information file. Note that if your paper is accepted for publication, this checklist will be published as part of your article. 3. Thank you for submitting the above manuscript to PLOS ONE. During our internal evaluation of the manuscript, we found significant text overlap between your submission and the following previously published works, some of which you are an author. - https://pubmed.ncbi.nlm.nih.gov/33544723/ - https://www.frontiersin.org/articles/10.3389/fphys.2021.648056/full We would like to make you aware that copying extracts from previous publications, especially outside the methods section, word-for-word is unacceptable. In addition, the reproduction of text from published reports has implications for the copyright that may apply to the publications. Please revise the manuscript to rephrase the duplicated text, cite your sources, and provide details as to how the current manuscript advances on previous work. Please note that further consideration is dependent on the submission of a manuscript that addresses these concerns about the overlap in text with published work. We will carefully review your manuscript upon resubmission, so please ensure that your revision is thorough. 4. Thank you for stating the following in the Funding Section of your manuscript: "This work was supported by Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP, 05/54362-4, 12/18492-4, 13/12486-5 and 14/50938-8), Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) and Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq, 465699/2014-6)." We note that you have provided funding information. However, funding information should not appear in the Funding section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form. Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows: "This work was supported by Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP, 05/54362-4, 12/18492-4, 13/12486-5 and 14/50938-8), Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) and Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq, 465699/2014-6)." Please include your amended statements within your cover letter; we will change the online submission form on your behalf. 5. Your ethics statement should only appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please delete it from any other section. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Partly Reviewer #2: No ********** 2. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: Yes Reviewer #2: No ********** 3. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: Yes Reviewer #2: Yes ********** 4. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: No Reviewer #2: No ********** 5. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: Gomes and colleagues extend their previous work investigating the relationship between maternal protein restriction during pregnancy and reduced nephron number in the offspring to consider the HIF1-α signalling cascade in the metanephros at gestational day 17. They observed a reduction in nephrogenic areas which was associated with the upregulation (mRNA and immunostaining for protein) of a number of key molecules in the HIF1-α signalling cascade and propose that this contributes to premature maturation of the kidney leading to lower nephron number. The experimental design is straightforward; however the manuscript would benefit from editing to improve the English as at times it is difficult to follow the narrative. Although this work is a continuation of previous reports from this group, in the interests of clarity for the current paper the authors should provide justification for only studying male fetuses. Why were females not considered too? Similarly, what was the rationale for selecting gestational day 17 for this study? Nephrogenesis in the rat commences on GD 13 and is not complete until postnatal day 10, so can a single snap shot on GD 17 provide a complete picture explaining why fewer nephrons develop in LP rats? An explanation for choosing GD17 is necessary to help place the study into context. In selecting the fetuses used in subsequent analyses was any consideration given to their position in the uterine horns? Were they selected at random; and if so, how were they randomised? Were equal numbers taken from the right and left horns? Please clarify whether the two-kidney pool used for the RTqPCR analysis represents two kidneys from one fetus or one kidney from two fetuses. More detail regarding the quantification of the immunostaining is required. How many fetal kidneys were taken from each litter? How many sections were taken from each kidney? Did you score serial sections (in which case structures will be duplicated over several sections) or did you sample 1 section every n sections? What do the data points in the graphs in figures 3-10 represent: individual sections or kidneys? Please clarify the n number. Do the data shown in figures 3-10 come from the same sub-set of kidneys/fetuses or were sections taken across multiple litters? Clarification of where each set of kidneys was derived would be helpful: it is not immediately clear why the study required 36 NP and 51 LP litters to generate the experimental tissue based on the current description of the methods. The Kolmogorov-Smirnov test is not ideal; there are better tests of normality, particularly for small n numbers, such as the Shapiro-Wilk test or the D'Agostino-Pearson test. The description of figure 1 in the results text refers to ‘areas occupied by CAP and comma-shaped vesicles’. Presumably this refers to nephrogenic cortex/metanephron area [this should be metanephros]; please clarify. Also, please define CAP: reference is made to ‘cap metanephric’ and ‘mesenchymal cap’ but these are abbreviated to CM. The legend for figure 2 states that ‘The authors established a cutoff point variation of 1.3 (upwards) or 0.65 (downwards)’. How was this done and what is the justification for these values? There is a mismatch between the figure numbers used in the results text and the figure legends / figures themselves. For example, mTOR is shown in figure 4 but in the text it is listed as figure 3; conversely TGF-β1 is shown in figure 3 but in the text it is listed as figure 4. HSP90, NFκB and NOS2 are depicted in figures 7, 8 and 9 but are described in the results text as figures 8, 9 and 10. VEGF is shown in figure 10 (but without representative immunostaining images) but is not mentioned in the results text. Similarly, the discussion refers to VEGF mRNA but this is not shown in figure 2. Why are the summary data for TGF-β1 shown in figure 3 as a bar graph whereas similar data in figures 4-10 are shown as scatter plots? The latter are more informative, so I suggest that the format of figure 3 is changed for consistency. The image quality for figures 5-9 could be improved. The results text frequently describes changes in the intracellular distribution of protein expression, but this is not easy to see in the images included in the figures. The discussion attempts to explain the observed changes in signalling molecule expression and their relationship with HIF1-α and nephron number. However, this should be tempered by acknowledgement that this study represents a snap shot picture at GD 17; whereas nephrogenesis normally extends until postnatal day 10. Reviewer #2: This study attempts to investigate the molecular changes in the kidneys of rat offspring who were exposed to a low protein environment in utero. While this study is novel and of potential interest to readers of PLOSone, the manuscript itself is not well written, some of the study procedures are confusing and the conclusions are not supported by the data shown. The abstract does not provide a clear rationale and is not sufficiently detailed in terms of the methods or results. The introduction should at least be separated into paragraphs and is somewhat confusing and very difficult to read. The authors introduce the topic of miRNAs and yet no miRNAs are examined in this study. There is also no clear rationale provided as to why this study is important. The methods section is a little more clearly written however there are several inconsistencies. The authors state that samples were collected for NGS, yet no methods or results are provided. The sex-determination is written as though it was only done in males. Why were only males selected for this study - this should be outlined. qPCR methods state the housekeep was GAPDH but the next section refers to 3 housekeeping genes? The sequences of the housekeeping genes should also be included in the table. The section "analysis of gene expression' also mentions quantifying miRNA levels yet no data is reported or discussed and methods are missing. immunohistochemistry - how were kidneys perfused?what was fixative? how many offspring kidneys were examined on the study? from how many different litters? Statistical Analysis should take into account the effect of litter, i.e. repeated measures analysis. Results - several of the results mentioned in the first paragraph of this section are not shown. it is unclear what "six2 positive cells" are. The immunohistochemistry images are not particularly convincing, negative control images should be shown and labels on figures should be defined in the figure legends. Why are immunohistochemistry images for VEGF not shown? Why are some sections counterstained and others not? Overall this section is not very convincing Discussion is extremely difficult to read and convoluted. Much emphasis is placed on HIF-1a but I am not convinced by the data and question the specificity of the antibodies used. In particular, the study has shown only associations and not cause and thus should be toned down. I was unclear how the conclusions about renal cell maturation, progenitor cell division etc fit in with this study. ********** 6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No Reviewer #2: No [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step. |
| Revision 1 |
|
PONE-D-22-07908R1IMPACT OF MATERNAL PROTEIN RESTRICTION ON HYPOXIA-INDUCIBLE FACTOR (HIF) EXPRESSION IN MALE FETAL KIDNEY DEVELOPMENTPLOS ONE Dear Dr. Gontijo, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that improvements have been made to the manuscript but it still does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that further addresses the points raised during the review process. Please submit your revised manuscript by Nov 24 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:
If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols. We look forward to receiving your revised manuscript. Kind regards, Christopher Torrens Academic Editor PLOS ONE [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation. Reviewer #1: (No Response) Reviewer #3: (No Response) ********** 2. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Partly Reviewer #3: No ********** 3. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: No Reviewer #3: (No Response) ********** 4. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: Yes Reviewer #3: No ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: No Reviewer #3: No ********** 6. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: The authors have addressed most of the points raised in my initial review; however there are several issues that require further attention. Although the manuscript has been edited extensively, there are still instances where the English could be improved to aid clarity. I am not convinced by the argument put forward for only studying male fetuses. Sex is indeed a complication; however it has been shown in numerous developmental programming studies that there are important differences in the way that males and females respond to intrauterine challenges. Best practice now requires that both sexes are considered in studies of this nature. Similarly, I am not convinced by the argument for only looking at gestational day 17. Nephrogenesis is a dynamic process that takes place both pre- and postnatally in the rat. Selecting one gestational day provides a snapshot of development at that point, but it does not tell you if there were compensatory changes at a later stage of development. This should be recognised as a limitation in the discussion and the overall conclusions toned down. The authors have resolved some of the issues over presentation in figures 3-8; however they have not clarified how the data presented in the graphs were collected. If I understand correctly, 5 NP and 5 LP litters were used for the immunostaining studies and one male fetus from each litter was sampled. Looking at the scatter plots in figures 3-8 there are many more than 5 data points for each group, which suggests that multiple sections have been taken from each kidney and individual data points have been analysed. If that is the case, then the number of replicates is artificially inflated, which in turn will affect the statistical analysis as the number of technical replicates is much greater than the number of biological replicates. A better approach would be to quantify expression in n sections per kidney and then take the mean value of those n sections as being representative of that individual kidney and fetus. In that way, the number of data points entered into the analysis and represented in the scatter plot should equal 5 per group. Reviewer #3: This study is of potential interest to readers of PLOSone. Unfortunately, the manuscript is not well written. Writing style and English usage are not appropriate. Some of the study procedures are confusing. Data are not clearly presented. Bibliography regarding fetal programming is not complete (no paper from Barker). Relevant articles regarding human nephrogenesis and a putative role of hypoxia (Gerosa C et al, Int Urol Nephrol 2017, 49, 1621) are missing. Conclusions are difficult to read, confusing, not well written, and not completely supported by the data shown in this manuscript. ********** 7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No Reviewer #3: No ********** [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step. |
| Revision 2 |
|
PONE-D-22-07908R2IMPACT OF MATERNAL PROTEIN RESTRICTION ON HYPOXIA-INDUCIBLE FACTOR (HIF) EXPRESSION IN MALE FETAL KIDNEY DEVELOPMENTPLOS ONE Dear Dr. Gontijo, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Specifically, there are still some issues in the presentation of the manuscript, particularly around language and grammar, that need to be addressed. Please submit your revised manuscript by Mar 10 2023 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:
If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols. We look forward to receiving your revised manuscript. Kind regards, Christopher Torrens Academic Editor PLOS ONE Journal Requirements: Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation. Reviewer #1: All comments have been addressed Reviewer #3: All comments have been addressed ********** 2. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Yes Reviewer #3: Partly ********** 3. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: Yes Reviewer #3: I Don't Know ********** 4. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: Yes Reviewer #3: Yes ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes Reviewer #3: No ********** 6. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: (No Response) Reviewer #3: the authors are encouraged to extensively re-write their manuscript. This last version of the paper is characterized by too many errors and mistakes. The bad English does not allow the rider to understand the meaning of too many sentences. Moreover, the fusion of the results and conclusions, in the absence of a discussion, in the abstract is not correct. The authors are encouraged to summarize the most important results and, subsequently, to discuss them on the basis of previous data reported in the literature. Some terms like “cuts”, not used in the laboratory practice, should be deleted. “Sections” might be much more appropriate. In the section “Materials and methods” some sentences should be accurately revised by a pathologist or by a technician with expertise in immunohistochemistry. To use eosin in sections immunostained for antigens expressed in the cytoplasm is not appropriate. ********** 7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No Reviewer #3: No ********** [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step. |
| Revision 3 |
|
IMPACT OF MATERNAL PROTEIN RESTRICTION ON HYPOXIA-INDUCIBLE FACTOR (HIF) EXPRESSION IN MALE FETAL KIDNEY DEVELOPMENT PONE-D-22-07908R3 Dear Dr. Gontijo, We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org. If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, Christopher Torrens Academic Editor PLOS ONE Additional Editor Comments (optional): Reviewers' comments: |
| Formally Accepted |
|
PONE-D-22-07908R3 Impact of maternal protein restriction on Hypoxia-Inducible Factor (HIF) expression in male fetal kidney development Dear Dr. Gontijo: I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department. If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org. If we can help with anything else, please email us at plosone@plos.org. Thank you for submitting your work to PLOS ONE and supporting open access. Kind regards, PLOS ONE Editorial Office Staff on behalf of Dr. Christopher Torrens Academic Editor PLOS ONE |
Open letter on the publication of peer review reports
PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.
We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.
Learn more at ASAPbio .